Data-Driven Prediction of Nanoparticle Biodistribution from Physicochemical Descriptors
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Nanoparticles have gained significant attention in biomedicine, electronics, and environmental science due to their unique physicochemical properties, which critically influence their absorption, distribution, metabolism, and excretion behavior in biological systems. However, predicting nanoparticle biodistribution and pharmacokinetics remains challenging due to the complexity of biological systems and the reliance on animal-derived data for physiologically based pharmacokinetic (PBPK) modeling. To address these limitations, this study integrates PBPK modeling with quantitative structure–activity (QSAR) relationship principles and multivariate linear regression (MLR) to develop a predictive framework for nanoparticle biodistribution based solely on physicochemical properties, using biodistribution data from healthy mice. Focusing exclusively on nondissolvable nanoparticles, we employed Bayesian analysis with Markov chain Monte Carlo simulations to fit PBPK models and generate kinetic parameters. The MLR–PBPK framework demonstrated strong predictive accuracy for kinetic indicators (adjusted R 2 up to 0.9) and successfully simulated nanoparticle biodistribution across 18 experiments. Key physicochemical properties such as zeta potential, size, and coating were identified as the most influential predictors, while the core material and shape had lesser impacts. Despite its success, the model faced limitations in predicting concentration–time curves for certain nanoparticles, highlighting the need for expanded data sets and nonlinear modeling approaches. This study provides a robust, nonanimal alternative for nanoparticle risk assessment, advancing safe and sustainable by design (SSbD) frameworks and offering a valuable tool for early-stage nanoparticle evaluation and design.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticles: synthesis and applications · Computational Drug Discovery Methods · Gold and Silver Nanoparticles Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Empa, Swiss Federal Laboratories for Materials Science and Technology, Nanomaterials in Health Laboratory, Lerchenfeldstrasse 5, St. Gallen 9014, Switzerland
Empa, Swiss Federal Laboratories for Materials Science and Technology, Technology and Society Laboratory, Lerchenfeldstrasse 5, St. Gallen 9014, Switzerland
Funding
European Commission · Staatssekretariat f?r Bildung, Forschung und Innovation · Animalfree Research Foundation
References (71)
Show source-provided references
1. 10.1039/c2cs15294k10.1039/c2cs15294k ↗
2. 10.1038/srep0703710.1038/srep07037 ↗
3. 10.1016/S1748-0132(06)70048-210.1016/S1748-0132(06)70048-2 ↗
4. 10.1146/annurev-bioeng-071811-15012410.1146/annurev-bioeng-071811-150124 ↗
5. 10.1002/smll.20110000110.1002/smll.201100001 ↗
6. 10.1126/science.111439710.1126/science.1114397 ↗
7. 10.1289/ehp.733910.1289/ehp.7339 ↗
8. John A. T. · 2022 · 3510.1007/978-3-030-72173-2_5 ↗
9. 10.1016/j.impact.2017.07.00610.1016/j.impact.2017.07.006 ↗
10. 10.1021/nn101881810.1021/nn1018818 ↗
11. 10.1021/acsptsci.4c0025010.1021/acsptsci.4c00250 ↗
12. OECD. Important Issues on Risk Assessment of Manufactured Nanomaterials; OECD Series on the Safety of Manufactured Nanomaterials and Other Advanced Materials; OECD Publishing: Paris, 2022.
13. 10.1098/rsif.2009.0252.focus10.1098/rsif.2009.0252.focus ↗
14. 10.3109/17435390.2014.94040410.3109/17435390.2014.940404 ↗
15. 10.3109/17435390.2015.102731410.3109/17435390.2015.1027314 ↗
16. 10.1126/sciadv.aax264210.1126/sciadv.aax2642 ↗
17. Caldeira, C.; Farcal, L. R.; Garmendia Aguirre, I.; Mancini, L.; Tosches, D.; Amelio, A.; Rasmussen, K.; Rauscher, H.; Riego Sintes, J.; Sala, S. Safe and Sustainable by Design Chemicals and Materials: Framework for the Definition of Criteria and Evaluation Procedure for Chemicals and Materials. EUR 31100 EN; Publications Office of the European Union: Luxembourg, 2022.
18. 10.1016/j.csbj.2024.05.01810.1016/j.csbj.2024.05.018 ↗
19. 10.1039/D2SU00101B10.1039/D2SU00101B ↗
20. 10.1039/D4SU00310A10.1039/D4SU00310A ↗
21. 10.1016/j.impact.2024.10053310.1016/j.impact.2024.100533 ↗
22. 10.1021/nn101348410.1021/nn1013484 ↗
23. 10.1021/acs.molpharmaceut.1c0071810.1021/acs.molpharmaceut.1c00718 ↗
24. 10.1021/acs.molpharmaceut.2c0002710.1021/acs.molpharmaceut.2c00027 ↗
25. 10.1016/j.jconrel.2024.08.01510.1016/j.jconrel.2024.08.015 ↗
26. 10.1021/acsnano.3c0403710.1021/acsnano.3c04037 ↗
27. 10.1016/j.jconrel.2023.07.04010.1016/j.jconrel.2023.07.040 ↗
28. 10.2147/IJN.S4662410.2147/IJN.S46624 ↗
29. 10.1021/cm100023p10.1021/cm100023p ↗
30. Buist, H. E. Characterization and Application of Physiologically Based Phamacokinetic Models in Risk Assessment; World Health Organization: Geneva, 2010.
31. 10.1080/01621459.1963.1050084510.1080/01621459.1963.10500845 ↗
32. 10.1063/5.003220810.1063/5.0032208 ↗
33. 10.3109/17435390.2013.86340610.3109/17435390.2013.863406 ↗
34. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
35. 10.1038/nbt.333010.1038/nbt.3330 ↗
36. 10.1038/nmat244210.1038/nmat2442 ↗
37. James G. · 2021 · 5910.1007/978-1-0716-1418-1_3 ↗
38. 10.1109/34.7551210.1109/34.75512 ↗
39. 10.1021/acsnano.9b0382410.1021/acsnano.9b03824 ↗
40. 10.1214/aos/101320345110.1214/aos/1013203451 ↗
41. 10.1016/S0146-6453(03)00002-210.1016/S0146-6453(03)00002-2 ↗
42. 10.1016/j.addr.2023.11470810.1016/j.addr.2023.114708 ↗
43. 10.1016/j.taap.2008.12.02310.1016/j.taap.2008.12.023 ↗
44. 10.1016/j.toxlet.2011.04.03410.1016/j.toxlet.2011.04.034 ↗
45. 10.2131/jts.33.29310.2131/jts.33.293 ↗
46. 10.1016/j.jconrel.2016.01.02010.1016/j.jconrel.2016.01.020 ↗
47. 10.1038/s41578-018-0038-310.1038/s41578-018-0038-3 ↗
48. 10.1002/jps.260068112910.1002/jps.2600681129 ↗
49. 10.1002/jps.260075031010.1002/jps.2600750310 ↗
50. 10.1016/0378-5173(87)90219-510.1016/0378-5173(87)90219-5 ↗
51. 10.1016/j.nano.2016.04.00810.1016/j.nano.2016.04.008 ↗
52. 10.1007/s10967-012-2173-410.1007/s10967-012-2173-4 ↗
53. 10.1007/s00204-009-0488-x10.1007/s00204-009-0488-x ↗
54. 10.1016/j.taap.2010.02.01310.1016/j.taap.2010.02.013 ↗
55. 10.1016/j.colsurfb.2018.04.00510.1016/j.colsurfb.2018.04.005 ↗
56. 10.1021/nn102430310.1021/nn1024303 ↗
57. 10.2217/nnm.12.6010.2217/nnm.12.60 ↗
58. 10.2165/00003088-200342100-0000210.2165/00003088-200342100-00002 ↗
59. 10.3389/fimmu.2020.0106610.3389/fimmu.2020.01066 ↗
60. van Furth R. · Bull. World Health Organ. · 1972 · 46 · 845
61. 10.1002/cphy.c12002610.1002/cphy.c120026 ↗
62. 10.3389/fimmu.2015.0048010.3389/fimmu.2015.00480 ↗
63. 10.18637/jss.v033.i0310.18637/jss.v033.i03 ↗
64. Moré J. J. · 1978 · 10510.1007/BFb0067700 ↗
65. Marin J.-M. · 2007
66. 10.1080/01621459.1996.1047670810.1080/01621459.1996.10476708 ↗
67. 10.1007/s11222-006-9438-010.1007/s11222-006-9438-0 ↗
68. 10.2307/331873710.2307/3318737 ↗
69. 10.1080/10618600.1998.1047478710.1080/10618600.1998.10474787 ↗
70. 10.1093/comjnl/10.3.27110.1093/comjnl/10.3.271 ↗
71. 10.1007/s00357-014-9161-z10.1007/s00357-014-9161-z ↗